Zacks Investment Research cut shares of Bioverativ (NASDAQ:BIVV) from a buy rating to a hold rating in a report published on Wednesday morning.
According to Zacks, “Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. “
BIVV has been the subject of a number of other reports. Royal Bank of Canada initiated coverage on shares of Bioverativ in a report on Thursday, September 14th. They set a sector perform rating and a $59.00 price objective for the company. Piper Jaffray Companies reaffirmed an overweight rating and set a $71.00 price objective on shares of Bioverativ in a report on Monday, October 23rd. Morgan Stanley reaffirmed an underweight rating and set a $47.00 price objective (up from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Argus raised shares of Bioverativ from a hold rating to a buy rating and set a $64.00 price objective for the company in a report on Wednesday, September 20th. Finally, Deutsche Bank set a $53.00 price objective on shares of Bioverativ and gave the stock a hold rating in a report on Monday, November 20th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of Hold and a consensus target price of $60.33.
Shares of Bioverativ (BIVV) traded up $0.70 during trading hours on Wednesday, reaching $56.09. 555,400 shares of the company’s stock traded hands, compared to its average volume of 1,220,000. Bioverativ has a 1 year low of $40.00 and a 1 year high of $64.41. The company has a market cap of $6,070.00 and a P/E ratio of 13.71.
Bioverativ (NASDAQ:BIVV) last posted its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The company had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. The firm’s quarterly revenue was up 27.2% compared to the same quarter last year. equities research analysts predict that Bioverativ will post 2.45 earnings per share for the current year.
Large investors have recently modified their holdings of the stock. BP PLC purchased a new position in Bioverativ in the 3rd quarter worth $799,000. Whittier Trust Co. of Nevada Inc. purchased a new position in Bioverativ in the 3rd quarter worth $293,000. Catalyst Capital Advisors LLC purchased a new position in Bioverativ in the 3rd quarter worth $5,707,000. American Century Companies Inc. purchased a new position in Bioverativ in the 3rd quarter worth $48,168,000. Finally, BNP Paribas Arbitrage SA purchased a new position in Bioverativ in the 3rd quarter worth $21,728,000. Institutional investors own 95.99% of the company’s stock.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.